Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel formulations

a technology of aqueous liquid and formulation, applied in the field of rapid acting aqueous liquid formulation, can solve the problems of greatly reducing stability and increasing the rapidity of action, and achieve the effects of rapid onset of action, high concentration of insulin compound, and rapid speed of action

Pending Publication Date: 2019-09-19
ARECOR LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides insulin formulations that are fast-acting and stable. These formulations have a high concentration of insulin compound and are more stable than formulations without non-ionic surfactant. The formulations use zinc and a zinc binding species to accelerate the onset of action of a high concentration insulin compound formulation. Overall, the invention provides a rapid and stable insulin formulation suitable for the treatment of diabetes.

Problems solved by technology

As noted in the background discussion above, use of EDTA to chelate zinc ions in hexameric insulin does increase the rapidity of action but at the cost of greatly reduced stability.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel formulations

Examples

Experimental program
Comparison scheme
Effect test

example 1 — example

Example 1—Example Formulations

[0270]The following example formulations may be prepared:

example a

[0271]

Insulin aspart1000 U / mlSodium phosphate2 mMphenol15.9 mMm-cresol15.9 mMIonic zinc (as ZnCl2)197 μg / ml (3 mM), equals 0.55% (w / w) based onthe weight of insulin compound in the formulationCitric acid44 mMGlycerol174 mMSurfactantSelected from A1, A2 or A3 (see below)Water for injectionqsResidual NaClAcidification and subsequent neutralisation duringpreparation results in formation of 2-4 mM NaClpH adjusted to 7.4Example A1: surfactant = dodecyl maltoside (0.05 mg / ml)Example A2: surfactant = polysorbate 20 (Tween 20) (0.05 mg / ml)Example A3: surfactant = polyethylene glycol (2) dodecyl ether (Brij L4) (0.05 mg / ml)

example b

[0272]

Insulin aspart1000 U / mlSodium phosphate2 mMphenol15.9 mMm-cresol15.9 mMIonic zinc (as ZnCl2)197 μg / ml (3 mM), equals 0.55% (w / w) based onthe weight of insulin compound in the formulationCitric acid44 mMGlycerol174 mMSurfactantSelected from B1, B2 or B3 (see below)Water for injectionqsResidual NaClAcidification and subsequent neutralisation duringpreparation results in formation of 2-4 mM NaClpH adjusted to 7.8Example B1: surfactant = dodecyl maltoside (0.05 mg / ml)Example B2: surfactant = polysorbate 20 (Tween 20) (0.05 mg / ml)Example B3: surfactant = polyethylene glycol (2) dodecyl ether (Brij L4) (0.05 mg / ml)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

There is provided inter alia an aqueous liquid pharmaceutical formulation comprising (i) an insulin compound at a concentration of 500-1000 U / ml, (ii) ionic zinc, (iii) a zinc binding species at a concentration of 1 mM or more selected from species having a logK with respect to zinc ion binding in the range 4.5-12.3 at 25° C., and (iv) a non-ionic surfactant; and wherein the formulation is substantially free of EDTA and any other zinc binding species having a logK with respect to zinc ion binding of more than 12.3 at 25° C.

Description

FIELD OF THE INVENTION[0001]This invention relates inter alia to rapid acting aqueous liquid formulations of insulin and insulin analogues. Such compositions are suitable for the treatment of subjects suffering from diabetes mellitus, especially Type I diabetes mellitus.BACKGROUND OF THE INVENTION[0002]Diabetes mellitus (“diabetes”) is a metabolic disorder associated with poor control of blood sugar levels leading to hypo or hyperglycaemia. Untreated diabetes can lead to serious microvascular and macrovascular complications including coronary artery disease, peripheral artery disease, stroke, diabetic nephropathy, neuropathy and retinopathy. The two main types of diabetes are (i) Type 1 diabetes resulting from the pancreas not producing insulin for which the usual treatment is insulin replacement therapy and (ii) Type 2 diabetes where patients either produce insufficient insulin or have insulin resistance and for which treatments include insulin sensitising agents (such as metformin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/28A61K31/194A61K47/26A61K47/34A61M5/315A61M5/142A61M5/32
CPCA61M5/31591A61M5/31593A61K38/28A61M5/142A61K47/34A61K31/194A61K47/26A61M5/32A61K9/0019A61K38/063A61K33/30A61P3/10A61P43/00A61P5/50A61K47/02A61K47/10A61K47/12A61K47/18A61K9/08A61K2300/00A61K45/06
Inventor GERRING, DAVIDHOWELL, SARAHJEZEK, JANZAKRZEWSKI, LEON
Owner ARECOR LTD
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com